Skip to Main Content

Washington has never before been so focused on lowering prescription drug prices. But these biotech investors aren’t worried.

“Politics is politics,” Affinity Asset Advisors senior research analyst Patrick Nosker said of drug pricing legislation at a STAT event Tuesday in New York. “The whole political overhang is definitely going to be noise throughout the next year.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!